Dedicated to Research Since 1993
  •  

    info@genesismarketinsights.com

Global Clinical Trials Market by Design (Treatment Studies, Observational Studies) by Phase (Phase I, Phase II, Phase III, Phase IV) – Business Overview, Analysis and Industry Forecast 2017-2023

 Healthcare and Pharmaceuticals

Report Overview

Global Clinical Trials Market was valued at USD XX Billion in the year 2017. Global Clinical Trials Market is further estimated to grow at a CAGR of XX % from 2018 to reach USD XX Billion by the year 2023.

North America region holds the highest market share in 2017 and is considered as the fastest growing market in the forecasted period. At the country level, U.S and Canada are the major markets and holds a substantial market share in 2017 and it is projected to grow at a gradual pace in the coming years.

The Clinical Trials market is segmented on the basis of design, by phase and region. By design, the market is categorized into treatment studies and observational studies. By phase, the market is segmented into, Phase I, Phase II, Phase III and Phase IV.

Drivers:

            Increasing Prevalence of Diseases

            High R&D Spending of the Pharmaceutical Industry

Restraints:

            Lack of Skilled Clinical Research Workforce

Opportunities:

            Demand for Clinical Trials in Emerging Markets

Challenges:

            Stringent Regulations for Patient Enrollment

Clinipace Worldwide (U.S), LabCorp (U.S), Eli Lilly and Company (U.S), ICON Plc. (Ireland), Novo Nordisk (Denmark), PAREXEL International Corporation (U.S), Pfizer Inc. (U.S), Pharmaceutical Product Development, LLC (U.S), IQVIA (U.S), and Roche Holding (Switzerland) among others are some of the key players in the Global Clinical Trials Market.

Key Benefits for Stakeholders

Clinical Research Organizations (CRO)

Healthcare associations and Industry associations

Government & Regulatory agencies and organizations

By Design

Treatment Studies

            Randomized Control Trial

            Adaptive Clinical Trial

            Non-Randomized Control Trial

Observational Studies

            Cohort Study

            Case Control Study

            Cross Sectional Study

            Ecological Study

By Phase

Phase I

Phase II

Phase III

Phase IV

By Region

North America

Europe

Asia-Pacific

RoW

Key Market Players

Clinipace Worldwide

LabCorp

Eli Lilly and Company

ICON Plc.

Novo Nordisk

PAREXEL International Corporation

Pfizer Inc.

Pharmaceutical Product Development, LLC

IQVIA

Roche Holding

(Another brief information of 10 companies will be provided in the report.)

Research Methodology:

Genesis Market Insights follows in-depth Research Methodology focused on reducing deviation in the collected data. GMI offers the most precise evaluations and projection for the market numbers. GMI engages following Market Engineering techniques –

  1.      Raw Market Data is collected and compared with the Existing in-house Data on a broad front.
  2.      Both Bottom-Up and Top-Down approaches are analyzed for segmenting and estimating measurable aspects of the market.
  3.      To avoid bias, we filter the collected data collected from authenticated sources.
  4.      GMI has a well proven Statistical Modeling System for estimates and forecasts.
  5.      Further, the report findings are validated with the Industry Expert Panel on face to face or telephonic interviews.
  6.      Panelists are approached from Leading Enterprises across the value chain including manufacturers, suppliers, technology providers, domain experts and buyers so as to validate a thorough and balanced market overview.

Detailed customization is also available for you. Further, if the report listed above does not meet your key requirements. Our customized research report will analytically cover the required market information you need which will help you to plan your business decisions.

Table Of Content

1. Introduction

1.1 Market Vision

       1.1.1 Market Definition

       1.1.2 Market Scope

1.2 Limitations

1.3 Stakeholders

2. Research Methodology

2.1. Research Process

       2.1.1. Secondary Research

             2.1.1.1. Key Data from Secondary Research

       2.1.2. Primary Research

             2.1.2.1. Key Data from Primary Research

             2.1.2.2. Breakdowns of Primary Interviews

2.2. Market Size Estimation

       2.2.1. Bottom-Up Approach

       2.2.2. Top-Down Approach

       2.2.3. Annual Revenue Process

2.3. Data Triangulation 

2.4. Research Assumptions 

       2.4.1. Assumption

3. Executive Summary

4. Market Overview

4.1. Introduction

4.2. Drivers

4.3. Restraints

4.4. Opportunities

4.5. Challenges

4.6. Regulations

4.7. Supply Chain/Value Chain Analysis

4.8. Patent & Standards

5. Industry Trends

5.1. Introduction

5.2. Porter’s Five Forces Analysis

       5.2.1. Threat of New Entrants

       5.2.2. Threat of Substitutes

       5.2.3. Bargaining Power of Buyers

       5.2.4. Bargaining Power of Suppliers

       5.2.5. Intensity of Competitive Rivalry

6. Global Clinical Trials Market, By Design

6.1 Treatment Studies

            6.1.1 Randomized Control Trial

            6.1.2 Adaptive Clinical Trial

            6.1.3 Non-Randomized Control Trial

6.2 Observational Studies

            6.2.1 Cohort Study

            6.2.2 Case Control Study

            6.2.3 Cross Sectional Study

            6.2.4 Ecological Study

7. Global Clinical Trials Market, By Phase

7.1 Phase I

7.2 Phase II

7.3 Phase III

7.4 Phase IV

8. Geographical Analysis

8.1. Introduction

8.2. North America

       8.2.1. U.S.

       8.2.2. Canada

       8.2.3. Mexico

8.3. Europe

       8.3.1. U.K.

       8.3.2. Germany

       8.3.3. Italy

       8.3.4. France

       8.3.5. RoE

8.4. Asia Pacific

       8.4.1. South Korea

       8.4.2. China

       8.4.3. Japan

       8.4.4. South Korea

       8.4.5. RoAPAC

8.5. RoW

       8.5.1. Latin America

       8.5.2. Middle East and Africa

9. Company Profiles

(Business Overview, Financial Overview, Product write Up, Recent Developments)

9.1 Clinipace Worldwide

9.2 LabCorp

9.3 Eli Lilly and Company

9.4 ICON Plc.

9.5 Novo Nordisk

9.6 PAREXEL International Corporation

9.7 Pfizer Inc.

9.8 Pharmaceutical Product Development, LLC

9.9 IQVIA

9.10 Roche Holding

(Another brief information of 10 companies will be provided in the report.)

10. Competitive Analysis

10.1. Introduction

10.2. Market Positioning of Key Players

10.3 Competitive Strategies Adopted by Leading Players

        10.3.1. Investments & Expansions

        10.3.2. New Product Launches

        10.3.3. Mergers & Acquisitions

        10.3.4. Agreements, Joint Ventures, and Partnerships

11. Appendix

11.1. Questionnaire

11.2. Available Customizations 

11.3. Upcoming Events (Trade Fair, Exhibitions, Conferences)

* The list of tables and figures will be provided in the sample report.

Summary

No Content Available.

PURCHASE OPTIONS

ASK FOR SPECIAL PRICING

Related Reports